Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
14.50
-0.73 (-4.79%)
At close: Apr 28, 2026, 4:00 PM EDT
14.52
+0.02 (0.14%)
After-hours: Apr 28, 2026, 6:31 PM EDT
Janux Therapeutics Employees
Janux Therapeutics had 109 employees as of December 31, 2025. The number of employees increased by 28 or 34.57% compared to the previous year.
Employees
109
Change (1Y)
28
Growth (1Y)
34.57%
Revenue / Employee
$91,743
Profits / Employee
-$1,042,431
Market Cap
882.06M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Maravai LifeSciences Holdings | 435 |
| MeiraGTx Holdings | 403 |
| Phathom Pharmaceuticals | 371 |
| Xencor | 260 |
| Sana Biotechnology | 142 |
| Theravance Biopharma | 90 |
| CytomX Therapeutics | 69 |
JANX News
- 1 day ago - Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development - Business Wire
- 12 days ago - Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 - Business Wire
- 27 days ago - Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Business Wire
- 2 months ago - Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights - Business Wire
- 2 months ago - Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 - Business Wire
- 3 months ago - Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer - Business Wire
- 3 months ago - Janux Therapeutics Strikes Bristol Myers Biotech Deal Worth $800 Million - Benzinga
- 3 months ago - Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug - Reuters